The economic impact of hypercholesterolemia and mixed dyslipidemia: A systematic review of cost of illness studies.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE
    • Publication Information:
      Original Publication: San Francisco, CA : Public Library of Science
    • Subject Terms:
      Cost of Illness*; Dyslipidemias/*economics ; Hypercholesterolemia/*economics; Humans ; Public Health/economics
    • Abstract:
      Hypercholesterolemia is a clinically relevant condition with an ascertained role in atherogenesis. In particular, its presence directly correlates to the risk of atherosclerotic cardiovascular disease (ASCVD). As known, cardiovascular diseases pose a significant economic burden worldwide; however, a clear picture of the economic impact of ASCVD secondary to hypercholesterolemia is lacking. This study aiming at conducting a systematic review of the current literature to assess the economic impact of familial hypercholesterolemia (FH), non-familial hypercholesterolemia (non-FH) or mixed dyslipidemia. A literature search was performed in Medline/PubMed and Embase database up to September 1st, 2020, exploring evidence published from 2010. The literature review was conducted in accordance with PRISMA guidelines. To be included the studies must be conducted on people who have been diagnosed with familial hypercholesterolemia, non-familial hypercholesterolemia or mixed dyslipidemia, and report data/information on costs attributable to these conditions and their sequelae. A total of 1260 studies were retrieved. After reading the titles and abstract, 103 studies were selected for full reading and eight met the criteria for inclusion. All but one studies were published in the American continent, with the majority conducted in US. An observational design with a prevalence approach were used and all estimated the economic burden of CVD. Direct cost estimates as annual average health expenditure on all population, ranging from $17 to $259 million. Few studies assessing the economic impact of hypercholesterolemia are available in the literature and new researches are needed to provide a more updated and reliable picture. Despite this scarceness of evidence, this review adds important data for future discussion on the knowledge of the economic impact of hypercholesterolemia and costs of care associated to this condition, with important implication for public health researches and novel therapies implementation.
      Competing Interests: PAC has received a research grant from Angelini, and speaking honoraria from Pfizer and Roche outside the submitted work; LGM has received grants and personal fees from Bayer AG, Boehringer Ingelheim, Pfizer, and Daiichi-Sankyo outside the submitted work. This does not alter our adherence to PLOS ONE policies on sharing data and materials. PF and DDL declare no conflicts of interest.
    • References:
      J Am Heart Assoc. 2019 Jul 2;8(13):e011822. (PMID: 31256702)
      NCHS Data Brief. 2012 Aug;(103):1-8. (PMID: 23101933)
      Obes Facts. 2017;10(3):261-272. (PMID: 28601866)
      Prev Cardiol. 2010 Spring;13(2):78-83. (PMID: 20377810)
      Clin Drug Investig. 2021 May;41(5):459-468. (PMID: 33725323)
      Value Health. 2010 Jan-Feb;13(1):87-94. (PMID: 19695008)
      Int J Cardiol. 2011 Jul 1;150(1):111-2. (PMID: 21605921)
      Anatol J Cardiol. 2018 Oct;20(4):235-240. (PMID: 30297582)
      BMJ Open Diabetes Res Care. 2020 Jul;8(1):. (PMID: 32747385)
      Turk Kardiyol Dern Ars. 2019 Sep;47(6):487-497. (PMID: 31483303)
      Adv Ther. 2015 Nov;32(11):1104-16. (PMID: 26585336)
      PLoS One. 2016 Jul 13;11(7):e0159129. (PMID: 27411042)
      BMC Cardiovasc Disord. 2016 Jan 14;16:13. (PMID: 26769473)
      Int J Technol Assess Health Care. 2005 Spring;21(2):240-5. (PMID: 15921065)
      BMJ. 2021 Mar 29;372:n160. (PMID: 33781993)
      Am J Cardiol. 2018 Oct 1;122(7):1128-1132. (PMID: 30086877)
      Arch Endocrinol Metab. 2018 Jun;62(3):303-308. (PMID: 29791657)
      Value Health Reg Issues. 2018 Dec;17:56-63. (PMID: 29684901)
    • Publication Date:
      Date Created: 20210712 Date Completed: 20211122 Latest Revision: 20240402
    • Publication Date:
      20240402
    • Accession Number:
      PMC8274865
    • Accession Number:
      10.1371/journal.pone.0254631
    • Accession Number:
      34252164